Glucagon-like peptide-1 receptor (GLP-1R) agonists, initially developed for the treatment of type 2 diabetes (T2D) and obesity, have emerged as promising agents with significant cardiovascular benefits beyond glycemic control [4,5,6,7,8,9,10,11,12,13]. Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.